These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25880290)

  • 1. Phosphodiesterase-5 inhibitors: emerging nephroprotective drugs.
    Abassi Z; Armaly Z
    Anatol J Cardiol; 2015 Apr; 15(4):311-2. PubMed ID: 25880290
    [No Abstract]   [Full Text] [Related]  

  • 2. The protective effect of single dose tadalafil in contrast-induced nephropathy: an experimental study.
    Özbek K; Ceyhan K; Koç F; Söğüt E; Altunkaş F; Karayakalı M; Çelik A; Kadı H; Köseoğlu RD; Önalan O
    Anatol J Cardiol; 2015 Apr; 15(4):306-10. PubMed ID: 25880289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
    Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
    J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction.
    Tanaka H; Kubo M; Nii M; Maki S; Umekawa T; Ikeda T
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1205-1208. PubMed ID: 28503744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
    Magee AG; Makhecha S; Bentley S
    Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanovesicular carrier-mediated transdermal delivery of tadalafil: i-formulation and physicsochemical characterization.
    Mehanna MM; Motawaa AM; Samaha MW
    Drug Dev Ind Pharm; 2015 May; 41(5):714-21. PubMed ID: 24669976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers.
    Baek JS; Pham CV; Myung CS; Cho CW
    Int J Pharm; 2015 Nov; 495(2):701-9. PubMed ID: 26423175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism.
    Nardozza A; Cabrini MR
    Rev Assoc Med Bras (1992); 2017 Aug; 63(8):689-692. PubMed ID: 28977106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).
    Russell A; Chatterjee S; Seed M
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25917070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
    Amano T; Earle C; Imao T; Matsumoto Y; Kishikage T
    Aging Male; 2018 Mar; 21(1):77-82. PubMed ID: 28830281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tadalafil therapy on kidney damage caused by sepsis in a polymicrobial septic model induced in rats: a biochemical and histopathological study.
    Benli E; Ayyildiz SN; Cirrik S; Koktürk S; Cirakoglu A; Noyan T; Ayyildiz A; Germiyanoglu C
    Int Braz J Urol; 2017; 43(2):345-355. PubMed ID: 27622284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
    Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
    Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and dose-finding trial of tadalafil administered for fetal growth restriction: A phase-1 clinical study.
    Kubo M; Tanaka H; Maki S; Nii M; Murabayashi N; Osato K; Kamimoto Y; Umekawa T; Kondo E; Ikeda T
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1159-1168. PubMed ID: 28718213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-a-day Tadalafil administration improves the spermogram parameters in fertile patients.
    Corvasce A; Albino G; Leonetti T; Buonomo AF; Marucco EC
    Arch Ital Urol Androl; 2015 Sep; 87(3):210-3. PubMed ID: 26428642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic and Ultrastructural Changes in Seminiferous Tubules of Adult Male Albino Rats Following Daily Administration of Different Doses of Tadalafil.
    Eid AA; Badr El Dine FM; Nabil IM
    Urology; 2016 Apr; 90():89-96. PubMed ID: 26772640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses.
    Peng Z; Yang L; Dong Q; Wei Q; Liu L; Yang B
    Urol Int; 2017; 99(3):343-352. PubMed ID: 28628914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction.
    Karabakan M; Keskin E; Akdemir S; Bozkurt A
    Int Braz J Urol; 2017; 43(2):317-324. PubMed ID: 27819758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy--Results from a Randomized Controlled Trial (REACTT).
    Mulhall JP; Brock G; Oelke M; Fode M; Probst KA; Henneges C; d'Anzeo G; Rossi A; Büttner H
    J Sex Med; 2016 Apr; 13(4):679-83. PubMed ID: 27045264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
    Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
    Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
    Bishara B; Abu-Saleh N; Awad H; Ghrayeb N; Goltsman I; Aronson D; Khamaysi I; Assady S; Armaly Z; Haddad S; Haddad E; Abassi Z
    Eur J Heart Fail; 2012 Oct; 14(10):1104-11. PubMed ID: 22740510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.